Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for shingles pain sufferers: drug trial underway

NCT ID NCT06708416

Symptom relief Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests an experimental drug called ONO-1110 to see if it can safely reduce pain in people with postherpetic neuralgia, a type of nerve pain that persists after a shingles infection. About 140 Japanese adults with pain lasting at least 3 months will receive either the drug or a placebo. The main goal is to measure changes in average pain scores over 8 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

142 people

The number who actually took part.

Started

Feb 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Japanese (both sexes) * Age (at the time of informed consent): 18 years and older * Outpatient * Patients with persistent pain ≥3 months (90 days) after the onset of herpes zoster * Patients who are considered capable of understanding the study procedures and completing the pain diary and questionnaires appropriately by the investigator (sub-investigator) Exclusion Criteria: * Patients who previously underwent neurodestruction or neurosurgical therapy for PHN * Patients with pain other than PHN that may affect assessments in this study * Patients with any skin condition related to the site of herpes zoster that may affect assessments in this study * Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study * Patients with concurrent psychiatric diseases that may affect assessments in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postherpetic neuralgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neuralgia, Postherpetic postherpetic neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postherpetic neuralgia

Contacts and locations

Locations

  • Central Japan International Medical Center

    Gifu, Japan

  • Chutoen General Medical Center

    Shizuoka, Japan

  • Fukuoka Tokushukai Hospital

    Fukuoka, Japan

  • Fukuuchi Pain Clinic

    Tokyo, Japan

  • Fukuwa Clinic

    Tokyo, Japan

  • Futaki Skin Care Clinic

    Tokyo, Japan

  • Juntendo University Hospital

    Tokyo, Japan

  • Junwakai Memorial Hospital

    Miyazaki, Japan

  • Kamezawa Clinic

    Aichi, Japan

  • Kawasaki Municipal Hospital

    Kanagawa, Japan

  • Kimura Clinic

    Aichi, Japan

  • Konan Hidamari Pain Clinic

    Kanagawa, Japan

  • Medical Corporation Fujigaki Clinic

    Ōita, Japan

  • Medical Corporation Toyama Dermatology

    Miyazaki, Japan

  • Mitaka Pain Clinic

    Tokyo, Japan

  • Mito Saiseikai General Hospital

    Ibaraki, Japan

  • Morimoto Clinic

    Osaka, Japan

  • National Hospital Organization Hokkaido Medical Center

    Hokkaido, Japan

  • National Hospital Organization Kure Medical Center

    Hiroshima, Japan

  • Nishinomiya Municipal Central Hospital

    Hyōgo, Japan

  • Nishiogi Pain Clinic

    Tokyo, Japan

  • Nomura Dermatology Clinic

    Kanagawa, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Osaka, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Shizuoka Rehabili Pain Clinic

    Shizuoka, Japan

  • Southern Tohoku General Hospital

    Fukushima, Japan

  • Tai Clinic

    Kanagawa, Japan

  • Tokyo-Eki Center-Building Clinic

    Tokyo, Japan

  • Yamanashi Prefectural Central Hospital

    Yamanashi, Japan

  • Yokohama City Minato Red Cross Hospital

    Kanagawa, Japan

  • Yuaikai Tomishiro Chuo Hospital

    Okinawa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.